



Press release from Emotra AB (publ)

Göteborg, June 9, 2021

Emotra signs agreement with National Institute of Mental Health in USA

After a period of discussions, an agreement for collaboration has been signed between National Institute of Mental Health (NIMH) in USA and Emotra. NIMH and Emotra will collaborate on animal studies to investigate the role of stress, hippocampal damages and hyporeactivity in rodents.

The agreement for collaboration is for exploratory research, where investigators plan to use the EDOR test to measure the effects of hippocampal changes on electrodermal hyporeactivity as a biomarker. The first contact with Heather Cameron as the chief of section of neuroplasticity was in May 2020 where a mutual interest and discussions on stress, neurogenesis and hippocampus has led to an exploratory research plan.

In this agreement, Emotra will provide know-how and equipment to the research group at NIMH that will conduct the experiments. These experiments are of exploratory nature, meaning that there are methodological and experimental challenges that can make this a short or a longer project.

Lars-Håkan Thorell, research and development manager in Emotra comments:

"I am very excited about the opportunity to work with researchers that possess a deep understanding of the hippocampal biology and skilled in this type of experiments. For Emotra and the EDOR method, this is a unique opportunity to gain more insight and better understand the underlying biological mechanisms linked to hyporeactivity. There is much that is unknown about the origin of hyporeactivity today and this project can provide us with new and valuable information that can open doors to new research questions".

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR[®], is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.